Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares

Rhea-AI Filing Summary

Bolt Biotherapeutics director Kathleen LaPorte received a stock option grant for 5,000 shares of common stock. The option has an exercise price of $4.43 per share and expires on June 9, 2036. It vests on the earlier of June 9, 2027 or the day immediately before the next annual stockholder meeting, assuming continuous service. The option will vest in full if there is a change in control of Bolt Biotherapeutics.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LAPORTE KATHLEEN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 5,000 shares Exercise price: $4.43 per share Expiration date: June 9, 2036 +1 more

4 metrics

Option grant size 5,000 shares Stock Option (Right to Buy) granted to director

Exercise price $4.43 per share Conversion or exercise price of the option

Expiration date June 9, 2036 Option expiration date

Vesting date June 9, 2027 Latest vesting date or earlier before next annual meeting

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, change in control, vest

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

change in control financial

"the option will vest in full upon a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

vest financial

"The shares subject to the option will vest on the earlier of June 9, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAPORTE KATHLEEN

(Last) (First) (Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.43	06/10/2026		A		5,000		(1)	06/09/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

	/s/ William P. Quinn, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Bolt Biotherapeutics (BOLT) report for Kathleen LaPorte?

Bolt Biotherapeutics reported that director Kathleen LaPorte received a grant of stock options for 5,000 shares. These options are a right to buy Bolt common stock under specified terms and are classified as a grant, award, or other acquisition.

What is the exercise price and size of the new Bolt Biotherapeutics (BOLT) option grant?

The new option grant to Kathleen LaPorte covers 5,000 shares of Bolt common stock at an exercise price of $4.43 per share. This price is the amount she would pay per share if she chooses to exercise the options in the future.

When do Kathleen LaPorte’s Bolt Biotherapeutics (BOLT) options vest?

The options vest on the earlier of June 9, 2027 or the day immediately before Bolt’s next annual stockholder meeting. Vesting requires that Kathleen LaPorte continue serving the company through that date under the terms disclosed.

What happens to the Bolt Biotherapeutics (BOLT) option grant if there is a change in control?

If there is a change in control of Bolt Biotherapeutics, the 5,000-share option granted to Kathleen LaPorte will vest in full. This means all option shares become exercisable upon such a change, according to the disclosed footnote terms.

How many Bolt Biotherapeutics (BOLT) options does Kathleen LaPorte hold after this grant?

After this grant, Kathleen LaPorte holds stock options covering 5,000 shares of Bolt common stock. This figure reflects the total option shares following the reported transaction, as stated in the Form 4 transaction details.